Cardiotoxicity from Cancer Treatments
Author Information
Author(s): Chan Stefanie Ho Yi, Layton Deborah, Webley Sherael, Salek Sam
Primary Institution: School of Life and Medical Sciences, University of Hertfordshire
Hypothesis
This study aimed to explore the association between non-small cell lung cancer treatments and cardiotoxicity.
Conclusion
The study found that alectinib has the highest reported risk of cardiovascular problems among NSCLC drugs, highlighting the need for continuous monitoring.
Supporting Evidence
- Alectinib had the highest reporting odds ratio for cardiovascular adverse events.
- The study analyzed 128,214 adverse events, with 6,133 being cardiovascular issues.
- Continuous monitoring of alectinib is essential to maintain a benefit-risk balance.
- Cardiotoxicity can range from mild to severe effects on heart function.
- Pharmacovigilance systems like the UK Yellow Card are crucial for patient safety.
- Signals for cardiovascular events were detected in 17 drugs using reporting odds ratio.
- Only alectinib and epirubicin showed significant signals for cardiovascular adverse reactions.
- Further studies are needed to establish causality between drugs and adverse reactions.
Takeaway
Some cancer treatments can hurt the heart, and this study looked at how often that happens with lung cancer drugs.
Methodology
A pharmacovigilance study using the UK Yellow Card System to analyze adverse event reports for 56 NSCLC drugs.
Potential Biases
The study may be biased due to over-reporting of newer drugs and under-reporting of well-established drugs.
Limitations
Under-reporting of adverse drug reactions and potential biases in the reporting system.
Participant Demographics
Demographics included various age groups and both genders, with specific signals detected in certain age and sex categories.
Statistical Information
P-Value
3.35
Confidence Interval
2.15 to 5.21
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website